The safety and efficacy of a JAK in – inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo - Kremer, JM; Bloom, BJ; Breedveld, FC (Arthritis Rheum, 2009)
et al.